



# MMWR

## Morbidity and Mortality Weekly Report

Weekly

February 22, 2002 / Vol. 51 / No. 7

### Laboratory-Acquired Meningococcal Disease — United States, 2000

*Neisseria meningitidis* is a leading cause of bacterial meningitis and sepsis among older children and young adults in the United States. *N. meningitidis* usually is transmitted through close contact with aerosols or secretions from the human nasopharynx. Although *N. meningitidis* is regularly isolated in clinical laboratories, it has infrequently been reported as a cause of laboratory-acquired infection. This report describes two probable cases of fatal laboratory-acquired meningococcal disease and the results of an inquiry to identify previously unreported cases. The findings indicate that *N. meningitidis* isolates pose a risk for microbiologists and should be handled in a manner that minimizes risk for exposure to aerosols or droplets.

#### Case Reports

**Case 1.** On July 15, 2000, an Alabama microbiologist aged 35 years presented to the emergency department of hospital A with acute onset of generalized malaise, fever, and diffuse myalgias. The patient was given a prescription for oral antibiotics and released. On July 16, the patient returned to hospital A, became tachycardic and hypotensive, and died 3 hours later. Blood cultures were positive for *N. meningitidis* serogroup C. Three days before the onset of symptoms, the patient had prepared a Gram's stain from the blood culture of a patient who was subsequently shown to have meningococcal disease; the microbiologist also had handled and subcultured agar plates containing cerebrospinal fluid (CSF) cultures of *N. meningitidis* serogroup C from the same patient. Co-workers reported that in the laboratory, aspiration of materials from blood culture bottles was performed at the open laboratory bench; biosafety cabinets, eye protection, or masks were not used routinely for this procedure. Results of pulsed-field gel electrophoresis (PFGE) and multilocus enzyme

electrophoresis (MEE) testing at CDC indicated that the two isolates were indistinguishable. The laboratory at hospital A infrequently processed isolates of *N. meningitidis* and had not processed another meningococcal isolate during the previous 4 years.

**Case 2.** On December 24, 2000, a Michigan microbiologist aged 52 years had acute onset of sore throat, vomiting, headache, and fever; by December 25, the patient had developed a petechial rash on both legs, which quickly evolved to widespread purpura. The patient presented to the emergency department of hospital B and died later that day of overwhelming sepsis. Blood cultures were positive for *N. meningitidis* serogroup C. The patient was a microbiologist in the state public health laboratory and had worked on several *N. meningitidis* serogroup C isolates during the 2 weeks before becoming ill. That laboratory had handled a median of four meningococcal isolates per month (range: 0–11) during the previous 4 years. Co-workers reported that the patient had performed slide agglutination testing and recorded colonial morphology using typical biosafety level 2 (BSL 2) precautions; this did not entail the use of a biosafety cabinet. PFGE was performed at the state public health laboratory and at CDC on all four specimens handled by the microbiologist; results of this testing indicated that the isolates from the patient and from one of the recently handled laboratory samples were indistinguishable.

#### INSIDE

- 144 Populations Receiving Optimally Fluoridated Public Drinking Water — United States, 2000
- 147 Socioeconomic Status of Women with Diabetes — United States, 2000

CENTERS FOR DISEASE CONTROL AND PREVENTION

SAFER • HEALTHIER • PEOPLE™

The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

#### SUGGESTED CITATION

Centers for Disease Control and Prevention. [Article Title]. *MMWR* 2002;51:[inclusive page numbers].

#### Centers for Disease Control and Prevention

Jeffrey P. Koplan, M.D., M.P.H.  
*Director*

David W. Fleming, M.D.  
*Deputy Director for Science and Public Health*

Dixie E. Snider, Jr., M.D., M.P.H.  
*Associate Director for Science*

#### Epidemiology Program Office

Stephen B. Thacker, M.D., M.Sc.  
*Director*

#### Office of Scientific and Health Communications

John W. Ward, M.D.  
*Director*

*Editor, MMWR Series*

David C. Johnson  
*Acting Managing Editor, MMWR (Weekly)*

Jill Crane  
Jeffrey D. Sokolow, M.A.  
*Writers/Editors, MMWR (Weekly)*

Lynda G. Cupell  
Beverly J. Holland  
*Visual Information Specialists*

Michele D. Renshaw  
Erica R. Shaver  
*Information Technology Specialists*

#### Division of Public Health Surveillance and Informatics

##### Notifiable Disease Morbidity and 122 Cities Mortality Data

Carol M. Knowles  
Deborah A. Adams  
Felicia J. Connor  
Patsy A. Hall  
Mechele A. Hester  
Pearl C. Sharp

To detect additional cases, on November 11, 2000, a request for information was posted on selected electronic mail discussion groups (i.e., listservs) to members of several infectious disease, microbiology, and infection control professional organizations. A probable case of laboratory-acquired meningococcal disease was defined as confirmed or probable meningococcal disease (*I*) in a laboratory scientist who had had occupational exposure to a *N. meningitidis* isolate during the 14 days before onset of illness and who had illness with a serogroup that matched the source isolate. In addition to the two cases described in this report, CDC received an additional 14 reports of probable laboratory-acquired meningococcal disease worldwide during the preceding 15 years; six cases occurred in the United States during 1996–2001. The source isolates from five of these six U.S. cases were from either blood or CSF; the source of the sixth isolate could not be definitively determined but was most likely CSF or middle ear fluid. Of these 16 previously unreported cases, nine (56%) were caused by *N. meningitidis* serogroup B, and seven (44%) were caused by serogroup C; eight cases (50%) were fatal (three from serogroup B and five from serogroup C). Case-fatality rates did not differ significantly by serogroups (serogroup C: 71%; serogroup B: 33%;  $p=0.16$ ). In the 10 cases for which data were available, a median of 4 days (range: 2–10 days) passed between handling the source isolate and symptom onset. Procedures performed on the 16 source isolates included reading plates (50%), making subcultures on agar plates (50%), and performing serogroup identification at the bench (38%). In 15 of the 16 cases, the laboratory reportedly did not perform procedures within a biosafety cabinet. All 16 cases occurred among workers in the microbiology section of the laboratory; no cases were reported among workers in hematology, chemistry, or pathology.

**Reported by:** J Lofgren, MD, B Whitley, MPH, Alabama Dept of Health; D Johnson, MD, F Downes, DrPH, State Public Health Laboratory; P Somsel, DrPH, B Robinson-Dunn, PhD, J Massey, DrPH, G Stoltzman, PhD, MG Stobierski, DVM, S Bidol, MPH, Michigan Dept of Community Health; C Hahn, MD, L Tengelton, DVM, Idaho Dept of Public Health; P Murray, PhD, American Society for Microbiology, Washington, DC; The Infectious Diseases Committee of the American Public Health Laboratories Association, Washington, DC; The College of American Pathologists, Waukegan, Illinois; D Sewell, PhD, National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania; W Schaffner, MD, Vanderbilt Univ School of Medicine, Nashville, Tennessee; D Stephens, Div of Infectious Diseases, Emory Univ School of Medicine, Atlanta, Georgia; M Miller, Div of Healthcare Quality Promotion; J Sejvar, MD, T Popovic, MD, B Perkins, MD, N Rosenstein, MD, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; National Institute for Occupational Safety and Health; Div of Laboratory Systems; Office of Health and Safety, CDC.

**Editorial Note:** Although the risk for disease remains low (2), laboratory-acquired meningococcal disease represents an occupational hazard to microbiologists. The findings in this report were self-reported and required respondents to have access to electronic media. However, the identification of 14 previously unreported cases and the additional two cases reported to CDC in 2001 suggest that either cases of laboratory-acquired meningococcal disease are underreported or the incidence of laboratory-acquired meningococcal disease has increased. The case-fatality rate of 50% in this report is substantially higher than that observed among community-acquired cases; this might reflect underreporting of mild cases or might be a result of the highly virulent strains and high concentration of organisms encountered in the laboratory setting.

Each year in the United States, approximately 3,000 isolates of invasive *N. meningitidis* are cultured (3); on the basis of standard practices used for isolation and identification of *N. meningitidis*, each of the clinical samples and isolates is handled by an average of three microbiologists during the course of a laboratory investigation, resulting in an estimated 9,000 microbiologists exposed per year. During 1996–2000 in the United States, six cases of probable laboratory-acquired meningococcal disease were detected, for an attack rate of 13 per 100,000 population (95% confidence interval [CI]=5–29) at risk per year, compared with approximately 0.2 per 100,000 population among adults aged 30–59 in the United States (CDC, unpublished data, 2001), the age group of most laboratory scientists. If the three cases from 2000 are excluded from this estimate, the attack rate is seven (95% CI=1–19).

*N. meningitidis* is classified as a biosafety level 2 organism (4). Guidelines recommend the use of a biosafety cabinet for mechanical manipulations of samples that have a substantial risk for droplet formation or aerosolization such as centrifuging, grinding, and blending procedures (4,5). Less is known about the risk associated with routine isolate manipulation.

The exclusive occurrence of probable laboratory-acquired cases in microbiologists suggests that exposure to isolates of *N. meningitidis*, and not patient samples, increases the risk for infection. Nearly all the microbiologists in this report were manipulating isolates and performing subculturing with an inoculation loop on an open laboratory bench. A recent study indicated that manipulating suspensions of *N. meningitidis* outside a biosafety cabinet is associated with a high risk for contracting disease (3). Isolates obtained from a respiratory source are in general less pathogenic and represent a lower risk for microbiologists.

Although the exact mechanism of transmission in the laboratory setting is unclear, use of a biosafety cabinet during manipulation of sterile site isolates of *N. meningitidis* would ensure protection. Alternative methods of protection (e.g., splash guards and masks) from droplets and aerosols require additional assessment. If a biosafety cabinet or other means of protection is unavailable, manipulation of these isolates should be minimized, and workers should consider sending specimens to laboratories possessing this equipment. Education of microbiologists and strict adherence to these safety precautions when manipulating meningococcal isolates should further minimize the risk for infection. To address these safety issues, the governing bodies of organizations responsible for setting policy for laboratory safety will be reassessing current guidelines about the handling of *N. meningitidis*.

Although primary prevention should focus on laboratory safety, laboratory workers also should make informed decisions about vaccination. The quadrivalent meningococcal polysaccharide vaccine, which includes serogroups A, C, Y, and W-135, will decrease but not eliminate the risk for infection (6). Research and industrial laboratory scientists who are exposed routinely to *N. meningitidis* in solutions that might be aerosolized also should consider vaccination (6–8). In addition, vaccination might be used as an adjunctive measure by microbiologists in clinical laboratories.

Laboratory scientists with percutaneous exposure to an invasive *N. meningitidis* isolate from a sterile site should receive treatment with penicillin; those with known mucosal exposure should receive antimicrobial chemoprophylaxis (6) (Table 1). Microbiologists who manipulate invasive *N. meningitidis* isolates in a manner that could induce aerosolization or droplet formation (including plating,

**TABLE 1. Schedule for administering chemoprophylaxis against meningococcal disease**

Drug	Age group	Dosage	Duration and route of administration*
Rifampin†	<1 month	5 mg/kg every 12 hours	2 days
	≥1 month	10 mg/kg every 12 hours	2 days
	Adults	600 mg every 12 hours	2 days
Ciprofloxacin§	Adults	500 mg	Single dose
Ceftriaxone	<15 years	125 mg	Single intramuscular dose
Ceftriaxone	Adults	250 mg	Single intramuscular dose

\* Oral administration unless otherwise indicated.

† Not recommended for pregnant women because the drug is teratogenic in laboratory animals. Because the reliability of oral contraceptives may be affected by rifampin therapy, consideration should be given to using alternative contraceptive measures while rifampin is being administered.

§ Not generally recommended for persons aged <18 years or for pregnant and lactating women because the drug causes cartilage damage in immature laboratory animals. However, ciprofloxacin can be used for chemoprophylaxis of children when no acceptable alternative therapy is available.

subculturing, and serogrouping) on an open bench top and in the absence of effective protection from droplets or aerosols also should consider antimicrobial chemoprophylaxis.

CDC has instituted prospective surveillance for laboratory-acquired meningococcal disease. Hospitals, laboratories, and public health departments that are aware of suspected cases should report these cases through their state public health department to CDC, telephone 404-639-3158.

#### References

1. CDC. Case definitions for infectious conditions under public health surveillance. MMWR 1997;46(No. RR-10).
2. Collins C, Kennedy D. Laboratory-acquired infections: history, incidence, causes, and preventions, 4th ed. Oxford, United Kingdom: Butterworth-Heinemann, 1999.
3. Bouter R, Stuart J. Assessing the risk of laboratory-acquired meningococcal disease [Abstract]. Presented at the Neisseria Meningitidis Meeting, Galveston, Texas, 2000.
4. CDC. Biosafety in microbiological and biomedical laboratories, 4th ed. Atlanta, Georgia: US Department of Health and Human Services, CDC, 1999.
5. National Committee for Clinical Laboratory Standards. Protection of laboratory workers from occupationally acquired infections: approved guideline, 2nd ed. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 2001 (document no. M29-A2).
6. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-7).
7. CDC. Laboratory-acquired meningococcemia—California and Massachusetts. MMWR 1991;40:46-7,55.
8. CDC. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices and the Hospital Infection Control Practices Advisory Committee. MMWR 1997;46(No. RR-18).

---

### Populations Receiving Optimally Fluoridated Public Drinking Water — United States, 2000

Dental caries (i.e., tooth decay) is a transmissible, multi-factor disease that affects 50% of children aged 5–9 years, 67% of adolescents aged 12–17 years (1), and 94% of adults aged  $\geq 18$  years (2) in the United States. During the second half of the 20th century (3), a major decline in the prevalence and severity of dental caries resulted from the identification of fluoride as an effective method of preventing caries. Fluoridation of the public water supply is the most equitable, cost-effective, and cost-saving method of delivering fluoride to the community (4,5). In the United States during 2000, approximately 162 million persons (65.8% of the population served by public water systems) received optimally fluoridated water compared with 144 million (62.1%) in 1992 (6). This report presents state-specific data on the status of water fluoridation

in the United States and describes a new surveillance system designed to routinely produce state and national data to monitor fluoridation in the public water supply. The results of this report indicate slow progress toward increasing access to optimally fluoridated water for persons using public water systems. Data from the new surveillance system can heighten public awareness of this effective caries prevention measure and can be used to identify areas where additional health promotion efforts are needed.

The 2000 and 2010 national health goals include objectives (13.9 and 21.9, respectively) (7,8) to increase the 1989 and 1992 national baseline fluoridation levels (61% and 62%, respectively) (6,9) to 75% of the U.S. population served by community water systems that receive water with optimal levels of fluoride (0.7–1.2 ppm depending on the average maximum daily air temperature of the area). The U.S. Environmental Protection Agency (EPA) does not regulate the addition of fluoride to water, and EPA's Safe Drinking Water Information System (SDWIS) actively tracks fluoride concentrations only in water systems with naturally occurring fluoride levels above the established regulatory limits ( $\geq 2.0$  ppm).

During 1998–2000, CDC developed the Water Fluoridation Reporting System (WFRS), a surveillance database that included CDC's 1992 water fluoridation census (6) and EPA's SDWIS. To ensure that initial data were accurate and complete, in 2000, CDC sent state-specific reports generated from WFRS to the oral health contact at each state health agency for review; updated information was returned, and nonrespondents were contacted through telephone calls and electronic messages. In July 2001, each state received its preliminary public water system data and was asked to submit corrections. Alabama, California, Kansas, Louisiana, Montana, Rhode Island, Texas, and Wyoming had not updated their data by September 1, 2001; therefore, existing WFRS data were used in this report.

Fluoridation percentages were determined by dividing the number of persons using public water systems with fluoride levels considered optimal (naturally occurring and adjusted) for the state by the total population of the state served by public water systems. When the population served by public water systems exceeded the 2000 population census for that state, the state census was used as the population using the public water supplies. This might occur as a result of the methods used by water systems to estimate the population served. These states were Alabama, Hawaii, Louisiana, Massachusetts, Missouri, Utah, and Wyoming.



In the United States during 2000, approximately 162 million persons (65.8% of the population served by public water systems) received optimally fluoridated water compared with 144 million (62.1%) in 1992 (6); state-specific percentages (Table 1) ranged from 2% (Utah) to 100% (District of Columbia) (median: 76.7%). In 27 states during 1992–2000, the proportion increased (range: 0.8%–63.8% [Georgia and Nevada, respectively]; median: 4.9%), and in 23 states, the proportion decreased (range: from –0.1% to –6.0% [Iowa and Alaska, respectively]; median: 2.9%); the District of Columbia remained 100% fluoridated. Delaware, Maine, Missouri, Nebraska, and Virginia reached 75% in 2000 and Oklahoma reached 74.6%. The national objective has been met by 26 states, and the small increase from 1992 to 2000 of 3.7 percentage points has left a gap of 9.2 percentage points from the overall target.

**Reported by:** D Apanian, MS, D Malvitz, DrPH, S Presson, DDS, Div of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

**Editorial Note:** WFRS data indicate that during the 1990s, the estimated proportion of the U.S. population using public water supplies that maintained optimally fluoridated water increased from 62.1% to 65.8%. This modest progress occurred as the result of substantial increases in coverage in a few states and, in some instances, because several large metropolitan areas commenced fluoridation (e.g., Clark County [Las Vegas], Nevada; Los Angeles and Sacramento, California; and Manchester, New Hampshire).

The findings in this report are subject to at least three limitations. First, nonresponses might have affected the accuracy of some states' final water fluoridation percentages by not accounting for changes in status. Second, use of the 2000 U.S. census data as the denominator for calculating water fluoridation percentages in seven states might have resulted in the percentages being underestimated because, in most states, the number of persons using public water systems was probably less than the 2000 U.S. census population. Finally, three states (Kentucky, Rhode Island, and South Dakota) reported their 1992 fluoridation rates as 100%; in these states, the apparent decrease from 1992 to 2000 in the percentage of persons using public water supplies receiving optimally fluoridated water represents an error correction in reporting methods rather than a true decrease.

WFRS will become an increasingly valuable tool for monitoring state and annually updating national water fluoridation data as more users register and routinely participate in entering data and receiving reports. WFRS updates and

reports will assist states in monitoring the extent and consistency of water fluoridation. During 2002, CDC will provide online information on water fluoridation for states that update their data electronically.

Although the new WFRS online site might facilitate public knowledge about optimally fluoridated water, efforts to convince jurisdictions to provide such water must address 1) the perception by some scientists, policymakers, and members of the public that dental caries is no longer a public health problem or that fluoridation is no longer necessary or effective; 2) the often complex political process involved in adopting water fluoridation; and 3) unsubstantiated claims by opponents of water fluoridation about its alleged adverse health effects (10). To reach the goal of 75% of the public water drinking population supplied with optimally fluoridated water, policymakers and public health officials at the federal, state, and local levels will need to devise new promotion and funding approaches to gain support for this prevention measure.

#### Acknowledgements

*This report is based on data contributed by state health, natural resources, and environmental departments. S Randlett, Alaska Dept of Environmental Conservation. K Hayward, Arizona Dept of Health Svcs. L Mouden, DDS, Arkansas Dept of Health. D Brunson, MPH, Colorado Dept of Public Health and Environment. H Link, Connecticut Dept of Public Health. H Davis, DDS, Florida Dept of Health. E Alderman, DDS, Georgia Dept of Human Resources. M Greer, DMD, Hawaii Dept of Health. L Penny, Idaho Dept of Health and Welfare. L Lampiris, DDS, Illinois Dept of Public Health. D Cain, Indiana State Dept of Health. M Magnant, Iowa Dept of Public Health. R Murphy, Kentucky Dept for Public Health. S Russ, Maine Dept of Human Svcs. N Reilman, Maryland Dept of the Environment. F Barker, Massachusetts Dept of Public Health. J Shekter, Michigan Dept of Environmental Quality. D Rindall, Minnesota Dept of Health. J Young, DMD, Mississippi State Dept of Health. M Logston, Missouri Dept of Natural Resources. K McFarland, DDS, Nebraska Health and Human Svcs System. C Lawson, Nevada State Health Div. A Pelletier, MD, New Hampshire Dept of Health and Human Svcs. F Dickert, New Jersey Dept of Environmental Protection. R Romero, DDS, New Mexico Dept of Health. E Green, DDS, New York State Dept of Health. R King, DDS, North Carolina Dept of Health and Human Svcs. G Stewart, MPA, North Dakota Dept of Health. J Pierson, Ohio Dept of Health. M Morgan, DDS, Oklahoma State Dept of Health. K Salis, Oregon Health Div. N Gardner, DDS, Pennsylvania Dept of Health. R Lala, DDS, South Carolina Dept of Health and Environmental Control. M Baker, South Dakota Dept of Health. W Wells, Tennessee Dept of Environment and Conservation. K Zinner, MPH, Utah Dept of Health. A Lund, Vermont Dept of Health. K Day, DDS, Virginia Dept of Health. T Wilson, Washington Dept of Health. G Black, DDS, West Virginia Bur of Public Health. W LeMay, DDS, Wisconsin Div of Public Health.*

**TABLE 1. Number of persons and percentage of the population receiving optimally fluoridated water through public water systems (PWS), by state — United States, 1992 and 2000**

State	2000 fluoridated population	2000 total PWS population	2000 percentage fluoridated	1992 percentage fluoridated (%)	Change in percentage 1992–2000
Alabama*	3,967,059	4,447,100	89.2%	82.6%	6.6
Alaska	270,099	489,371	55.2%	61.2%	-6.0
Arizona	2,700,354	4,869,065	55.5%	49.9%	5.6
Arkansas†	1,455,767	2,431,477	59.9%	58.7%	1.2
California	9,551,961	33,238,057	28.7%	15.7%	13.0
Colorado†	2,852,386	3,708,061	76.9%	81.7%	-4.8
Connecticut	2,398,227	2,701,178	88.8%	85.9%	2.9
Delaware	505,747	624,923	80.9%	67.4%	13.5
District of Columbia	595,000	595,000	100.0%	100.0%	0.0
Florida	9,407,494	15,033,574	62.6%	58.3%	4.3
Georgia	6,161,139	6,634,635	92.9%	92.1%	0.8
Hawaii*	109,147	1,211,537	9.0%	13.0%	-4.0
Idaho	383,720	845,780	45.4%	48.3%	-2.9
Illinois	10,453,837	11,192,286	93.4%	95.2%	-1.8
Indiana	4,232,907	4,441,502	95.3%	98.6%	-3.3
Iowa	2,181,649	2,390,661	91.3%	91.4%	-0.1
Kansas	1,513,306	2,421,274	62.5%	58.4%	4.1
Kentucky	3,235,053	3,367,812	96.1%	100.0%	-3.9
Louisiana*	2,375,702	4,468,976	53.2%	55.7%	-2.5
Maine	466,208	618,033	75.4%	55.8%	19.6
Maryland†	4,124,953	4,547,908	90.7%	85.8%	4.9
Massachusetts†*	3,546,099	6,349,097	55.8%	57.0%	-1.2
Michigan	6,568,151	7,242,531	90.7%	88.5%	2.2
Minnesota	3,714,465	3,780,942	98.2%	93.4%	4.8
Mississippi	1,227,268	2,665,075	46.0%	48.4%	-2.4
Missouri*	4,502,722	5,595,211	80.5%	71.4%	9.1
Montana	143,092	645,452	22.2%	25.9%	-3.7
Nebraska†	966,262	1,243,713	77.7%	62.1%	15.6
Nevada†	1,078,479	1,637,105	65.9%	2.1%	63.8
New Hampshire	347,007	807,438	43.0%	24.0%	19.0
New Jersey	1,120,410	7,208,514	15.5%	16.2%	-0.7
New Mexico	1,187,404	1,548,084	76.7%	66.2%	10.5
New York†	12,000,000	17,690,198	67.8%	69.7%	-1.9
North Carolina	4,862,220	5,837,936	83.3%	78.5%	4.8
North Dakota	531,738	557,595	95.4%	96.4%	-1.0
Ohio	8,355,002	9,535,188	87.6%	87.9%	-0.3
Oklahoma†	2,164,330	2,900,000	74.6%	58.0%	16.6
Oregon†	612,485	2,700,000	22.7%	24.8%	-2.1
Pennsylvania	5,825,328	10,750,095	54.2%	50.9%	3.3
Rhode Island	842,797	989,786	85.1%	100.0%	-14.9
South Carolina	3,086,974	3,383,434	91.2%	90.0%	1.2
South Dakota†	553,503	626,221	88.4%	100.0%	-11.6
Tennessee	4,749,493	5,025,998	94.5%	92.0%	2.5
Texas	11,868,046	18,072,680	65.7%	64.0%	1.7
Utah†*	43,816	2,233,169	2.0%	3.1%	-1.1
Vermont	240,579	443,901	54.2%	57.4%	-3.2
Virginia	5,677,551	6,085,436	93.3%	72.1%	21.2
Washington†	2,844,893	4,925,540	57.8%	53.2%	4.6
West Virginia†	1,207,000	1,387,000	87.0%	82.1%	4.9
Wisconsin	3,108,738	3,481,285	89.3%	93.0%	-3.7
Wyoming*	149,774	493,782	30.3%	35.7%	-5.4
<b>Total</b>	<b>162,067,341</b>	<b>246,120,616</b>	<b>65.8%</b>	<b>62.1%</b>	<b>3.7</b>

\* Reported PWS population exceeded total state population; PWS population was set to the 2000 U.S. census of state populations.

† Complete data were not available from Water Fluoridation Reporting System; additional information was obtained from states.

## References

1. Kaste LM, Selwitz RH, Oldakowski RJ, Brunelle JA, Winn DM, Brown LJ. Coronal caries in the primary and permanent dentition of children and adolescents 1–17 years of age: United States, 1988–1991. *J Dent Res* 1996;75:631–41.
2. Winn DM, Brunelle JA, Selwitz RH, et al. Coronal and root caries in the dentition of adults in the United States, 1988–1991. *J Dent Res* 1996;75:642–51.
3. CDC. Achievements in public health, 1900–1999: fluoridation of drinking water to prevent dental caries. *MMWR* 1999;48:933–40.
4. CDC. Recommendations for using fluoride to prevent and control dental caries in the United States. *MMWR* 2001;50(No. RR-14):26.
5. Griffin SO, Jones K, Tomar SL. An economic evaluation of community water fluoridation. *J Public Health Dent* 2001;61:78–86.
6. CDC. National Center for Prevention Services. Fluoridation census 1992 summary. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, CDC, 1993.
7. US Department of Health and Human Services. Healthy people 2000: national health promotion and disease prevention objectives—full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service, 1990:357–8.
8. US Department of Health and Human Services. Healthy people 2010—understanding and improving health. 2nd ed. Washington, DC: US Government Printing Office, November 2000:21–28.
9. CDC. National Center for Prevention Services. Fluoridation census 1989 summary. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, CDC, 1991.
10. Hodge HC. Evaluation of some objections to water fluoridation. In: Newbrun E, ed. *Fluorides and Dental Caries: Contemporary Concepts for Practitioners and Students*. 3rd ed. Springfield, Illinois: Charles C Thomas, 1986:221–55.

## Socioeconomic Status of Women with Diabetes — United States, 2000

Persons whose socioeconomic status is low have poorer health than other persons (1,2) and are less likely to have adequate access to care or to receive high-quality clinical and prevention care services (3). In the United States, diabetes is a potentially debilitating disease that is increasing in prevalence (4); however, little is known about the socioeconomic status of persons with diabetes (5–7). Women account for approximately 52% of all persons aged  $\geq 20$  years with diabetes (4). To assess the socioeconomic status of women with diabetes, CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS), which indicated that the socioeconomic status of women with diabetes in 2000 was markedly lower than that of women without diabetes. Efforts should be focused to understand the impact of socioeconomic conditions on the health and quality of care of women with diabetes.

BRFSS is a state-based, random-digit-dialed telephone survey of the noninstitutionalized U.S. population aged  $\geq 18$  years. In 2000, the median state-specific response rate was 48.9%

(range: 28.8%–71.8%) (CDC, unpublished data, 2001). Persons with diabetes were identified if they answered “yes” to the question, “Have you ever been told by a doctor that you have diabetes?” Women who answered “no” and those who had been told they had diabetes only during pregnancy were considered not to have diabetes. Data on level of education and annual household income were used to assess socioeconomic status; marital status, size of household, and employment status were used as indicators of living arrangements; and household size was derived by adding the number of adults and number of children aged  $\leq 17$  years. A woman was classified as having low socioeconomic status if she did not complete high school or resided in a household with an annual income of  $< \$25,000$ .

State-specific data were aggregated and weighted to reflect age, sex, and racial/ethnic distribution, and chi-square tests were used to test all univariate associations. Because many persons aged 18–24 years have not completed their education, socioeconomic status was evaluated only for women aged  $\geq 25$  years. Multivariate logistic regression analysis was used to examine the relation between having diabetes and not completing high school or living in a low-income household, with control made for age, race/ethnicity, and living arrangements. The models then were used to calculate adjusted percentages using the distributions of female respondents aged  $\geq 25$  years in the total population. All analyses were conducted using SASv8 software with SUDAAN to estimate standard errors.

Of the 109,680 women who participated in the 2000 BRFSS survey, 6,835 (6.3%) had been told by a doctor that they had diabetes (mean age at diagnosis: 48.8 years). Women with diabetes were more likely than women without diabetes to be aged  $\geq 45$  years; nonwhite; divorced, separated, or widowed; living alone; retired; or unable to work (Table 1).

Among women aged  $\geq 25$  years, the percentage with diabetes who had not completed high school (27.7%; 95% confidence interval [CI]=25.7%–29.7%) was more than twice that of women without diabetes who had not completed high school (12.2%; 95% CI=11.8%–12.6%) (Table 2). Among women with diabetes, 20.5% (95% CI=18.0%–25.3%) of those aged 25–44 years had not completed high school, compared with 34.3% (95% CI=31.4%–37.2%) of those aged  $\geq 65$  years. Among women without diabetes, 9.8% (95% CI=9.2%–10.3%) of those aged 25–44 years had not completed high school, compared with 20.5% (95% CI=19.5%–21.5%) of those aged  $\geq 65$  years. After multivariate adjustment, a low level of formal education remained significantly more common among women with diabetes than among those without diabetes.

**TABLE 1. Percentage of women aged  $\geq 18$  years with and without diabetes, by selected characteristics — Behavioral Risk Factor Surveillance System, United States, 2000**

Characteristic	Diabetes*		No diabetes*	
	%	(95% CI) <sup>†</sup>	%	(95% CI)
<b>Age (yrs)</b>				
18–24	1.4	(0.9–1.9)	12.6	(12.2–13.0)
25–44	14.7	(13.2–16.2)	39.6	(39.1–40.1)
45–64	42.1	(40.0–44.2)	29.1	(28.6–29.6)
$\geq 65$	41.9	(39.8–44.0)	18.7	(18.3–19.1)
<b>Race/Ethnicity</b>				
Non-Hispanic white	64.8	(62.6–67.0)	73.8	(73.2–74.3)
Non-Hispanic black	17.9	(16.3–19.5)	9.9	(9.6–10.2)
Hispanic	13.5	(11.6–15.4)	12.3	(11.9–12.7)
Non-Hispanic other	3.9	(2.7–5.1)	4.0	(3.7–4.3)
<b>Marital status</b>				
Married/Unwed couple	48.9	(46.7–51.0)	60.1	(59.6–60.6)
Divorced/Separated	16.6	(15.2–18.0)	13.4	(13.1–13.7)
Widowed	26.5	(24.6–28.4)	10.3	(10.0–10.6)
Never married	8.0	(6.8–9.2)	16.3	(15.9–16.7)
<b>Household size</b>				
1	25.9	(25.2–26.6)	15.6	(15.3–15.9)
2	37.9	(35.9–39.9)	32.7	(32.2–33.2)
3	15.7	(14.0–17.4)	18.6	(18.4–18.8)
$\geq 4$	20.5	(18.3–22.7)	33.1	(32.6–33.6)
<b>Employment status</b>				
Employed	31.8	(29.8–33.8)	57.5	(56.7–58.0)
Unemployed	4.4	(3.5–5.3)	8.2	(7.9–8.5)
Homemaker	13.2	(11.6–14.8)	14.1	(13.7–14.5)
Retired	35.5	(33.5–37.5)	16.6	(16.2–17.0)
Unable to work	15.1	(13.5–16.7)	3.6	(3.4–3.8)

\* Diabetes = 6,835 persons; no diabetes = 100,927.

<sup>†</sup> Confidence interval.

Overall, women with diabetes (40.4% [95%CI=38.1%–42.6%]) were approximately twice as likely as women without diabetes (22% [95%CI=21.5%–22.5%]) to have an annual household income  $< \$25,000$ . Among women with diabetes, the percentages with incomes  $< \$25,000$  were highest for women aged  $\geq 65$  years (47.8% [95%CI=44.4%–51.1%]) and those aged  $\leq 44$  years (41.3% [95%CI=35.4%–47.2%]) and lowest (33% [95%CI=29.5%–36.6%]) for women aged 45–64 years (Table 2). In each age group, percentages were lower for women without diabetes (32.9%, 19.7%, and 18.6%, respectively). After multivariate

adjustment, the difference between women with and without diabetes remained significant.

**Reported by:** GLA Beckles, MD, PE Thompson-Reid, MPH, Div of Diabetes Translation, National Center for Chronic Disease and Health Promotion, CDC.

**Editorial Note:** The findings in this report indicate that the socioeconomic status of women with diabetes is lower than that of women without diabetes and confirm the findings of the 1989 National Health Interview Survey (NHIS) (5). In 2000, at least one in four women with diabetes aged  $\geq 25$  years had a low level of formal education, and 40% lived in low-income households. Women with diabetes were more likely to have a low socioeconomic status independent of living arrangements (i.e., marital status, size of household, and employment status). Attaining a higher educational level might influence decision-making, and persons with a higher income might have better access to health care, higher living standards, and other material benefits that have a positive impact on health. Although socioeconomic status might be influenced adversely by factors related to having diabetes (e.g., being unemployed or retiring early), most women with diabetes in this survey were diagnosed long after they had completed their education. BRFSS estimates suggest that the low socioeconomic status of many women with diabetes might compromise their ability to benefit from treatments that might reduce their risks for complications and premature death. Programs designed to meet the needs of women with diabetes should take socioeconomic status into account to assure that women benefit from the interventions. Performance should be carefully evaluated to assess program effectiveness and identify areas for improvement.

The findings in this report are subject to at least three limitations. First, the low median response rate suggests the potential for participation bias. Second, all data were self-reported and might be subject to recall bias. Finally, the level of low socioeconomic status (i.e., household income  $< \$25,000$ ) among women with diabetes might be underestimated because 21% of women with diabetes declined to

**TABLE 2. Percentage of women with low socioeconomic status with and without diabetes, by age group — Behavioral Risk Factor Surveillance System, United States, 2000**


Age group (yrs)	No high school diploma				Annual household income $< \$25,000$			
	Diabetes		No diabetes		Diabetes		No diabetes	
	%	(95% CI) <sup>*</sup>	%	(95% CI)	%	(95% CI)	%	(95% CI)
25–44	20.5	(18.0–25.3)	9.8	(9.2–10.3)	41.3	(35.4–47.2)	19.7	(19.1–20.4)
45–64	23.7	(20.5–26.8)	10.4	(9.7–11.0)	33.0	(29.5–36.6)	18.6	(17.8–19.3)
$\geq 65$	34.3	(31.4–37.2)	20.5	(19.5–21.5)	47.8	(44.4–51.1)	32.9	(31.7–34.0)
<b>Unadjusted total</b>	<b>27.7</b>	<b>(25.7–29.7)</b>	<b>12.2</b>	<b>(11.8–12.6)</b>	<b>40.4</b>	<b>(38.1–42.6)</b>	<b>22.0</b>	<b>(21.5–22.5)</b>
<b>Adjusted total<sup>†</sup></b>	<b>18.0</b>	<b>(16.7–19.4)</b>	<b>13.0</b>	<b>(12.6–13.4)</b>	<b>37.0</b>	<b>(34.7–39.3)</b>	<b>27.0</b>	<b>(26.4–27.5)</b>

\* Confidence interval.

<sup>†</sup> Adjusted for age, race/ethnicity, marital status, size of household, and employment status.

(Continued on page 159)



**FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending February 16, 2002, with historical data**

\* No measles or rubella cases were reported for the current 4-week period yielding a ratio for week 7 of zero (0).

† Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

**TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending February 16, 2002 (7th Week)\***

	Cum. 2002	Cum. 2001		Cum. 2002	Cum. 2001
Anthrax	-	-	Encephalitis: West Nile†	4	-
Botulism:			Hansen disease (leprosy)†	3	9
foodborne	5	5	Hantavirus pulmonary syndrome†	-	1
infant	5	7	Hemolytic uremic syndrome, postdiarrheal†	8	16
other (wound & unspecified)	1	-	HIV infection, pediatric †§	4	10
Brucellosis†	7	5	Plague	-	-
Chancroid	3	7	Poliomyelitis, paralytic	-	-
Cholera	-	-	Psittacosis†	6	1
Cyclosporiasis†	11	21	Q fever†	3	-
Diphtheria	-	-	Rabies, human	-	-
Ehrlichiosis:			Streptococcal toxic-shock syndrome†	6	13
human granulocytic (HGE)†	5	4	Tetanus	-	5
human monocytic (HME)†	1	3	Toxic-shock syndrome	13	15
other and unspecified	-	-	Trichinosis	2	5
Encephalitis:			Tularemia†	4	1
California serogroup viral†	7	1	Yellow fever	-	-
eastern equine†	-	-			
Powassan†	-	-			
St. Louis†	-	-			
western equine†	-	-			

-: No reported cases.

\* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

† Not notifiable in all states.

§ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update January 27, 2002.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending February 16, 2002, and February 17, 2001 (7th Week)\*

Reporting Area	AIDS		Chlamydia†		Cryptosporidiosis		Escherichia coli			
							O157:H7		Shiga Toxin Positive, Serogroup non-O157	
	Cum. 2002†	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	3,550	4,178	71,342	95,443	211	195	132	126	6	4
NEW ENGLAND	119	87	2,659	2,994	7	4	6	9	-	-
Maine	1	3	174	162	-	-	-	-	-	-
N.H.	2	5	183	160	2	-	-	1	-	-
Vt.	2	5	96	89	-	2	-	-	-	-
Mass.	83	50	1,170	1,147	2	1	4	8	-	-
R.I.	6	9	358	431	3	1	2	-	-	-
Conn.	25	15	678	1,005	-	-	-	-	-	-
MID. ATLANTIC	874	2,021	6,185	8,254	16	30	7	13	-	-
Upstate N.Y.	52	489	900	1,079	3	4	7	9	-	-
N.Y. City	600	1,371	3,313	3,441	8	18	-	-	-	-
N.J.	163	131	263	993	-	2	-	4	-	-
Pa.	59	30	1,709	2,741	5	6	N	N	-	-
E.N. CENTRAL	375	217	10,418	18,793	58	73	41	28	-	-
Ohio	106	37	481	5,356	18	16	11	11	-	-
Ind.	53	26	1,667	1,927	8	8	3	4	-	-
Ill.	175	123	3,253	5,564	3	7	9	7	-	-
Mich.	31	23	3,880	3,592	14	11	8	1	-	-
Wis.	10	8	1,137	2,354	15	31	10	5	-	-
W.N. CENTRAL	47	46	2,743	5,160	16	5	21	11	3	-
Minn.	9	7	746	1,155	7	-	8	6	3	-
Iowa	15	9	-	426	2	2	7	-	-	-
Mo.	22	6	1,030	1,840	5	1	3	2	-	-
N. Dak.	-	-	37	133	-	-	-	-	-	-
S. Dak.	-	-	286	258	-	-	-	1	-	-
Nebr.	-	15	-	488	-	2	-	-	-	-
Kans.	1	9	644	860	2	-	3	2	-	-
S. ATLANTIC	1,156	709	14,748	18,234	52	30	23	14	1	2
Del.	23	14	181	391	-	-	1	-	-	-
Md.	143	39	1,905	1,997	1	2	-	-	-	-
D.C.	19	61	379	401	1	2	-	-	-	-
Va.	113	88	1,978	2,120	-	2	1	2	-	1
W. Va.	8	4	313	310	-	-	-	-	-	-
N.C.	64	33	2,558	2,080	7	4	4	6	-	-
S.C.	112	50	1,702	3,017	-	-	-	1	-	-
Ga.	377	104	1,936	4,116	38	9	16	3	1	1
Fla.	297	316	3,796	3,802	5	11	1	2	-	-
E.S. CENTRAL	158	126	6,213	6,509	11	3	1	4	-	-
Ky.	16	18	972	1,104	1	-	-	-	-	-
Tenn.	86	58	2,093	2,089	1	-	1	2	-	-
Ala.	20	25	2,197	1,620	8	2	-	2	-	-
Miss.	36	25	951	1,696	1	1	-	-	-	-
W.S. CENTRAL	401	385	12,165	14,507	4	4	-	15	-	-
Ark.	14	19	409	1,271	2	1	-	-	-	-
La.	75	117	2,329	2,435	1	1	-	-	-	-
Okla.	7	20	992	1,471	1	1	-	2	-	-
Tex.	305	229	8,435	9,330	-	1	-	13	-	-
MOUNTAIN	121	144	4,865	4,865	10	12	12	7	1	1
Mont.	3	1	364	159	-	-	1	-	-	-
Idaho	1	-	236	249	2	2	1	2	-	-
Wyo.	1	-	99	111	-	-	-	-	1	-
Colo.	21	51	644	1,346	4	5	2	2	-	1
N. Mex.	6	10	755	798	-	3	2	-	-	-
Ariz.	52	37	1,254	1,437	1	1	1	3	-	-
Utah	7	9	880	67	2	1	3	-	-	-
Nev.	30	36	633	698	1	-	2	-	-	-
PACIFIC	299	443	11,346	16,127	37	34	21	25	1	1
Wash.	-	28	1,842	1,871	10	U	4	3	-	-
Oreg.	76	18	-	858	7	3	7	-	1	-
Calif.	220	396	8,680	12,527	20	31	10	18	-	1
Alaska	-	1	434	313	-	-	-	-	-	-
Hawaii	3	-	390	558	-	-	-	4	-	-
Guam	1	1	-	-	-	-	N	N	-	-
P.R.	68	48	-	367	-	-	-	-	-	-
V.I.	33	1	-	24	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	20	U	-	U	-	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands.

\* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

† Chlamydia refers to genital infections caused by *C. trachomatis*.

‡ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update January 27, 2002.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending February 16, 2002, and February 17, 2001 (7th Week)\*

Reporting Area	Escherichia coli		Giardiasis	Gonorrhea		Haemophilus influenzae, Invasive			
	Shiga Toxin Positive, Not Serogrouped			All Ages, All Serotypes		Age <5 Years Serotype B			
	Cum. 2002	Cum. 2001		Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	1	1	1,293	33,495	45,972	182	198	-	2
NEW ENGLAND	-	-	141	847	830	7	7	-	1
Maine	-	-	23	13	23	1	-	-	-
N.H.	-	-	9	11	13	1	-	-	-
Vt.	-	-	16	13	14	-	-	-	-
Mass.	-	-	45	450	354	5	7	-	1
R.I.	-	-	18	119	109	-	-	-	-
Conn.	-	-	30	241	317	-	-	-	-
MID. ATLANTIC	-	-	240	2,996	4,141	31	33	-	-
Upstate N.Y.	-	-	60	501	604	16	7	-	-
N.Y. City	-	-	99	1,452	1,566	10	11	-	-
N.J.	-	-	-	225	584	2	12	-	-
Pa.	-	-	81	818	1,387	3	3	-	-
E.N. CENTRAL	1	-	273	5,490	9,728	26	39	-	-
Ohio	1	-	119	340	2,898	21	16	-	-
Ind.	-	-	-	771	912	3	3	-	-
Ill.	-	-	31	1,906	2,937	-	13	-	-
Mich.	-	-	100	2,078	2,124	1	3	-	-
Wis.	-	-	23	395	857	1	4	-	-
W.N. CENTRAL	-	-	127	1,448	2,278	2	3	-	-
Minn.	-	-	37	262	372	-	-	-	-
Iowa	-	-	34	-	113	1	-	-	-
Mo.	-	-	31	844	1,158	1	3	-	-
N. Dak.	-	-	-	-	4	-	-	-	-
S. Dak.	-	-	8	38	30	-	-	-	-
Nebr.	-	-	-	-	187	-	-	-	-
Kans.	-	-	17	304	414	-	-	-	-
S. ATLANTIC	-	-	222	9,328	11,997	55	58	-	1
Del.	-	-	10	141	217	-	-	-	-
Md.	-	-	17	1,075	1,156	16	12	-	-
D.C.	-	-	8	335	420	-	-	-	-
Va.	-	-	9	1,258	1,219	2	3	-	-
W. Va.	-	-	2	127	59	-	2	-	1
N.C.	-	-	-	2,087	1,733	5	6	-	-
S.C.	-	-	1	995	2,714	-	1	-	-
Ga.	-	-	103	1,236	2,283	22	19	-	-
Fla.	-	-	72	2,074	2,196	10	15	-	-
E.S. CENTRAL	-	1	34	3,825	4,410	3	4	-	-
Ky.	-	1	-	407	466	-	-	-	-
Tenn.	-	-	11	1,289	1,494	2	2	-	-
Ala.	-	-	23	1,477	1,359	1	2	-	-
Miss.	-	-	-	652	1,091	-	-	-	-
W.S. CENTRAL	-	-	9	5,726	7,472	9	2	-	-
Ark.	-	-	9	253	874	-	-	-	-
La.	-	-	-	1,574	1,699	-	-	-	-
Okla.	-	-	-	436	731	9	2	-	-
Tex.	-	-	-	3,463	4,168	-	-	-	-
MOUNTAIN	-	-	126	1,243	1,296	31	35	-	-
Mont.	-	-	5	24	6	-	-	-	-
Idaho	-	-	3	13	17	-	1	-	-
Wyo.	-	-	1	8	12	-	-	-	-
Colo.	-	-	50	433	474	7	7	-	-
N. Mex.	-	-	8	146	141	7	6	-	-
Ariz.	-	-	12	354	392	13	20	-	-
Utah	-	-	25	67	9	3	-	-	-
Nev.	-	-	22	198	245	1	1	-	-
PACIFIC	-	-	121	2,592	3,820	18	17	-	-
Wash.	-	-	22	407	420	-	-	-	-
Oreg.	-	-	76	-	151	13	-	-	-
Calif.	-	-	-	2,038	3,119	-	12	-	-
Alaska	-	-	10	95	37	-	1	-	-
Hawaii	-	-	13	52	93	5	4	-	-
Guam	-	-	-	-	-	-	-	-	-
P.R.	-	-	-	-	128	-	-	-	-
V.I.	-	-	-	-	3	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	1	U	-	U	-	-

N: Not notifiable. U: Unavailable. -: No reported cases.

\* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending February 16, 2002, and February 17, 2001 (7th Week)\*

Reporting Area	<i>Haemophilus influenzae</i> , Invasive				Hepatitis (Viral, Acute), By Type					
	Age <5 Years									
	Non-Serotype B		Unknown Serotype		A		B		C; Non-A, Non-B	
	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	27	37	-	3	830	1,872	394	737	130	691
NEW ENGLAND	1	3	-	-	48	68	14	18	3	9
Maine	-	-	-	-	1	1	-	1	-	-
N.H.	-	-	-	-	3	2	3	1	-	-
Vt.	-	-	-	-	-	1	1	1	3	2
Mass.	1	3	-	-	23	29	9	4	-	7
R.I.	-	-	-	-	4	2	1	-	-	-
Conn.	-	-	-	-	17	33	-	11	-	-
MID. ATLANTIC	2	4	-	-	66	172	63	185	24	313
Upstate N.Y.	2	-	-	-	14	16	4	6	4	6
N.Y. City	-	2	-	-	12	59	31	85	-	-
N.J.	-	-	-	-	1	75	8	71	18	298
Pa.	-	2	-	-	39	22	20	23	2	9
E.N. CENTRAL	4	7	-	-	81	602	57	71	10	46
Ohio	3	2	-	-	29	35	9	15	1	1
Ind.	1	-	-	-	2	5	2	2	-	-
Ill.	-	4	-	-	21	483	2	2	1	19
Mich.	-	-	-	-	26	68	44	52	8	26
Wis.	-	1	-	-	3	11	-	-	-	-
W.N. CENTRAL	-	-	-	1	44	77	17	28	36	161
Minn.	-	-	-	-	1	1	2	1	-	-
Iowa	-	-	-	-	13	5	5	4	-	-
Mo.	-	-	-	1	8	24	7	17	36	159
N. Dak.	-	-	-	-	-	-	-	-	-	-
S. Dak.	-	-	-	-	2	-	-	1	-	-
Nebr.	-	-	-	-	-	17	-	4	-	1
Kans.	-	-	-	-	20	30	3	1	-	1
S. ATLANTIC	7	8	-	-	249	192	118	143	10	6
Del.	-	-	-	-	-	1	1	3	3	1
Md.	-	-	-	-	67	38	14	16	2	1
D.C.	-	-	-	-	12	3	2	2	-	-
Va.	1	-	-	-	3	19	13	9	-	-
W. Va.	-	-	-	-	1	-	2	1	-	-
N.C.	-	-	-	-	42	5	34	26	3	1
S.C.	-	-	-	-	8	9	3	-	1	-
Ga.	3	5	-	-	39	70	21	64	-	1
Fla.	3	3	-	-	77	47	28	22	1	2
E.S. CENTRAL	1	-	-	1	28	38	11	50	19	10
Ky.	-	-	-	-	8	5	3	8	1	-
Tenn.	-	-	-	-	-	15	-	15	3	7
Ala.	1	-	-	1	5	17	8	14	2	-
Miss.	-	-	-	-	15	1	-	13	13	3
W.S. CENTRAL	4	1	-	-	13	338	14	45	-	125
Ark.	-	-	-	-	5	13	12	14	-	1
La.	-	-	-	-	-	14	-	19	-	52
Okla.	4	1	-	-	7	20	1	11	-	-
Tex.	-	-	-	-	1	291	1	1	-	72
MOUNTAIN	6	5	-	1	66	120	29	54	12	8
Mont.	-	-	-	-	2	2	-	-	-	-
Idaho	-	-	-	-	-	17	-	2	-	1
Wyo.	-	-	-	-	2	1	2	-	4	2
Colo.	1	-	-	-	15	17	11	13	6	1
N. Mex.	2	2	-	1	3	3	1	16	-	4
Ariz.	2	3	-	-	24	54	7	15	-	-
Utah	-	-	-	-	8	7	3	-	-	-
Nev.	1	-	-	-	12	19	5	8	2	-
PACIFIC	2	9	-	-	235	265	71	143	16	13
Wash.	-	-	-	-	7	5	2	5	-	-
Oreg.	2	-	-	-	20	1	17	3	6	1
Calif.	-	8	-	-	208	248	52	131	10	12
Alaska	-	-	-	-	-	10	-	1	-	-
Hawaii	-	1	-	-	-	1	-	3	-	-
Guam	-	-	-	-	-	-	-	-	-	-
P.R.	-	-	-	-	-	1	-	6	-	1
V.I.	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	-	U	4	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

\* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).



TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending February 16, 2002, and February 17, 2001 (7th Week)\*

Reporting Area	Legionellosis		Listeriosis		Lyme Disease		Malaria		Measles Total	
	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	76	98	30	45	361	582	104	153	-	23 <sup>†</sup>
NEW ENGLAND	3	2	1	4	16	80	8	15	-	4
Maine	-	-	1	-	-	-	1	-	-	-
N.H.	1	-	-	-	7	2	4	-	-	-
Vt.	-	1	-	-	-	-	-	-	-	1
Mass.	-	1	-	4	6	29	-	8	-	3
R.I.	-	-	-	-	3	-	-	-	-	-
Conn.	2	-	-	-	-	49	3	7	-	-
MID. ATLANTIC	12	20	5	5	264	407	12	36	-	-
Upstate N.Y.	3	1	3	1	166	111	3	1	-	-
N.Y. City	-	2	1	1	-	4	5	19	-	-
N.J.	-	4	-	2	16	86	2	10	-	-
Pa.	9	13	1	1	82	206	2	6	-	-
E.N. CENTRAL	35	37	5	7	7	23	10	30	-	-
Ohio	25	14	4	1	7	8	7	4	-	-
Ind.	1	2	-	-	-	-	-	6	-	-
Ill.	-	6	-	1	-	2	-	9	-	-
Mich.	9	9	1	3	-	-	3	11	-	-
Wis.	-	6	-	2	U	13	-	-	-	-
W.N. CENTRAL	1	6	-	1	6	3	6	4	-	-
Minn.	-	-	-	-	2	3	-	1	-	-
Iowa	-	1	-	-	2	-	2	-	-	-
Mo.	1	3	-	-	2	-	2	3	-	-
N. Dak.	-	-	-	-	-	-	-	-	-	-
S. Dak.	-	-	-	-	-	-	-	-	-	-
Nebr.	-	1	-	-	-	-	-	-	-	-
Kans.	-	1	-	1	-	-	2	-	-	-
S. ATLANTIC	14	9	6	3	52	47	40	30	-	3
Del.	3	-	-	-	5	4	-	1	-	-
Md.	4	5	1	1	37	40	15	12	-	3
D.C.	-	-	-	-	3	1	2	2	-	-
Va.	-	2	-	1	-	1	-	8	-	-
W. Va.	N	N	-	-	-	-	-	-	-	-
N.C.	1	-	-	-	-	-	4	1	-	-
S.C.	-	-	2	-	1	1	2	-	-	-
Ga.	3	1	2	1	-	-	11	4	-	-
Fla.	3	1	1	-	6	-	6	2	-	-
E.S. CENTRAL	-	6	2	4	-	2	2	1	-	-
Ky.	-	2	-	1	-	2	-	-	-	-
Tenn.	-	-	1	2	-	-	1	1	-	-
Ala.	-	2	1	1	-	-	1	-	-	-
Miss.	-	2	-	-	-	-	-	-	-	-
W.S. CENTRAL	-	2	-	3	1	11	-	2	-	-
Ark.	-	-	-	-	-	-	-	-	-	-
La.	-	1	-	-	-	-	-	1	-	-
Okla.	-	-	-	-	-	-	-	-	-	-
Tex.	-	1	-	3	1	11	-	1	-	-
MOUNTAIN	4	4	3	3	2	-	3	8	-	1
Mont.	-	-	-	-	-	-	-	1	-	-
Idaho	-	-	-	-	-	-	-	1	-	1
Wyo.	-	-	-	-	-	-	-	-	-	-
Colo.	1	3	1	1	1	-	2	3	-	-
N. Mex.	1	-	-	-	1	-	-	-	-	-
Ariz.	-	1	2	1	-	-	-	1	-	-
Utah	2	-	-	-	-	-	-	1	-	-
Nev.	-	-	-	1	-	-	1	1	-	-
PACIFIC	7	12	8	15	13	9	23	27	-	15
Wash.	-	1	-	-	-	-	-	-	-	11
Oreg.	N	N	1	1	1	1	-	2	-	2
Calif.	7	11	7	14	12	8	20	22	-	1
Alaska	-	-	-	-	-	-	1	1	-	-
Hawaii	-	-	-	-	N	N	2	2	-	1
Guam	-	-	-	-	-	-	-	-	-	-
P.R.	-	2	-	-	N	N	-	-	-	-
V.I.	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	-	U	-	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

\* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

<sup>†</sup> Of 23 cases reported, 19 were indigenous and four were imported from another country.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending February 16, 2002, and February 17, 2001 (7th Week)\*

Reporting Area	Meningococcal Disease		Mumps		Pertussis		Rabies, Animal	
	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	192	471	18	20	448	637	388	706
NEW ENGLAND	16	29	1	-	126	105	64	59
Maine	2	-	-	-	3	-	4	10
N.H.	1	1	1	-	1	6	1	-
Vt.	2	-	-	-	17	17	17	11
Mass.	8	20	-	-	105	80	19	16
R.I.	2	-	-	-	-	-	4	8
Conn.	1	8	-	-	-	2	19	14
MID. ATLANTIC	19	66	3	2	26	27	71	104
Upstate N.Y.	4	13	1	1	22	22	54	60
N.Y. City	4	12	-	1	-	4	4	-
N.J.	1	28	-	-	-	-	-	16
Pa.	10	13	2	-	4	1	13	28
E.N. CENTRAL	31	49	-	1	65	83	2	6
Ohio	17	13	-	1	43	57	1	-
Ind.	6	-	-	-	2	1	1	1
Ill.	-	11	-	-	10	1	-	-
Mich.	6	17	-	-	9	10	-	2
Wis.	2	8	-	-	1	14	-	3
W.N. CENTRAL	8	27	1	1	61	29	21	45
Minn.	-	-	-	-	1	-	3	11
Iowa	1	8	-	-	26	5	4	9
Mo.	4	12	-	-	22	15	1	2
N. Dak.	-	-	-	-	-	-	-	8
S. Dak.	2	-	-	-	2	2	-	7
Nebr.	-	2	-	-	-	-	-	-
Kans.	1	5	1	1	10	7	13	8
S. ATLANTIC	34	72	3	1	41	27	165	177
Del.	1	-	-	-	1	-	3	-
Md.	1	12	1	1	10	7	38	36
D.C.	-	-	-	-	-	-	-	-
Va.	2	7	1	-	12	-	54	41
W. Va.	-	-	-	-	-	-	10	13
N.C.	5	17	-	-	7	10	54	45
S.C.	2	4	1	-	10	4	6	7
Ga.	8	14	-	-	-	6	-	15
Fla.	15	18	-	-	1	-	-	20
E.S. CENTRAL	10	28	2	-	15	16	12	110
Ky.	-	3	-	-	4	3	1	2
Tenn.	1	9	-	-	9	8	7	106
Ala.	8	10	1	-	2	2	4	2
Miss.	1	6	1	-	-	3	-	-
W.S. CENTRAL	11	110	-	-	18	3	16	129
Ark.	5	6	-	-	5	2	-	-
La.	1	17	-	-	-	-	-	2
Okla.	4	6	-	-	1	1	16	10
Tex.	1	81	-	-	12	-	-	117
MOUNTAIN	22	22	-	2	76	282	15	33
Mont.	-	-	-	-	2	-	-	4
Idaho	-	3	-	-	5	45	-	-
Wyo.	-	-	-	1	1	-	1	10
Colo.	7	8	-	-	41	92	-	-
N. Mex.	-	4	-	1	12	8	-	-
Ariz.	7	3	-	-	9	133	14	19
Utah	4	2	-	-	5	4	-	-
Nev.	4	2	-	-	1	-	-	-
PACIFIC	41	68	8	13	20	65	22	43
Wash.	7	6	-	-	4	7	-	-
Oreg.	11	1	N	N	11	2	-	-
Calif.	21	57	8	7	3	49	8	21
Alaska	1	-	-	-	2	-	14	22
Hawaii	1	4	-	6	-	7	-	-
Guam	-	-	-	-	-	-	-	-
P.R.	-	-	-	-	-	-	11	16
V.I.	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	-	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

\* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending February 16, 2002, and February 17, 2001 (7th Week)\*

Reporting Area	Rocky Mountain Spotted Fever		Rubella				Salmonellosis	
			Rubella		Congenital Rubella			
	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	31	9	-	-	-	-	2,554	3,118
NEW ENGLAND	-	-	-	-	-	-	150	162
Maine	-	-	-	-	-	-	28	8
N.H.	-	-	-	-	-	-	4	11
Vt.	-	-	-	-	-	-	6	9
Mass.	-	-	-	-	-	-	76	121
R.I.	-	-	-	-	-	-	5	9
Conn.	-	-	-	-	-	-	31	4
MID. ATLANTIC	4	1	-	-	-	-	206	535
Upstate N.Y.	-	-	-	-	-	-	42	63
N.Y. City	-	-	-	-	-	-	80	133
N.J.	-	-	-	-	-	-	2	199
Pa.	4	1	-	-	-	-	82	140
E.N. CENTRAL	2	2	-	-	-	-	399	450
Ohio	2	-	-	-	-	-	108	140
Ind.	-	1	-	-	-	-	33	24
Ill.	-	-	-	-	-	-	140	139
Mich.	-	-	-	-	-	-	83	76
Wis.	-	-	-	-	-	-	35	71
W.N. CENTRAL	-	1	-	-	-	-	187	175
Minn.	-	-	-	-	-	-	43	56
Iowa	-	-	-	-	-	-	36	18
Mo.	-	1	-	-	-	-	76	47
N. Dak.	-	-	-	-	-	-	-	1
S. Dak.	-	-	-	-	-	-	11	13
Nebr.	-	-	-	-	-	-	-	13
Kans.	-	-	-	-	-	-	21	27
S. ATLANTIC	23	4	-	-	-	-	775	681
Del.	-	-	-	-	-	-	6	8
Md.	5	1	-	-	-	-	74	76
D.C.	-	-	-	-	-	-	9	13
Va.	-	-	-	-	-	-	70	73
W. Va.	-	-	-	-	-	-	3	1
N.C.	18	3	-	-	-	-	118	134
S.C.	-	-	-	-	-	-	31	49
Ga.	-	-	-	-	-	-	294	199
Fla.	-	-	-	-	-	-	170	128
E.S. CENTRAL	2	1	-	-	-	-	160	178
Ky.	-	-	-	-	-	-	18	31
Tenn.	2	1	-	-	-	-	46	34
Ala.	-	-	-	-	-	-	60	76
Miss.	-	-	-	-	-	-	36	37
W.S. CENTRAL	-	-	-	-	-	-	55	346
Ark.	-	-	-	-	-	-	27	25
La.	-	-	-	-	-	-	-	59
Okla.	-	-	-	-	-	-	26	12
Tex.	-	-	-	-	-	-	2	250
MOUNTAIN	-	-	-	-	-	-	190	162
Mont.	-	-	-	-	-	-	3	7
Idaho	-	-	-	-	-	-	10	6
Wyo.	-	-	-	-	-	-	4	8
Colo.	-	-	-	-	-	-	65	45
N. Mex.	-	-	-	-	-	-	26	26
Ariz.	-	-	-	-	-	-	34	44
Utah	-	-	-	-	-	-	17	15
Nev.	-	-	-	-	-	-	31	11
PACIFIC	-	-	-	-	-	-	432	429
Wash.	-	-	-	-	-	-	12	14
Oreg.	-	-	-	-	-	-	39	5
Calif.	-	-	-	-	-	-	348	360
Alaska	-	-	-	-	-	-	9	5
Hawaii	-	-	-	-	-	-	24	45
Guam	-	-	-	-	-	-	-	-
P.R.	-	-	-	-	-	-	3	79
V.I.	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	-	U	1	U

N: Not notifiable. U: Unavailable. -: No reported cases.

\* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending February 16, 2002, and February 17, 2001 (7th Week)\*

Reporting Area	Shigellosis		Streptococcal Disease, Invasive, Group A		Streptococcus pneumoniae, Drug Resistant, Invasive		Streptococcus pneumoniae, Invasive (<5 Years)	
	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
UNITED STATES	1,453	1,659	410	528	213	368	12	12
NEW ENGLAND	28	19	15	18	1	2	6	-
Maine	2	-	4	5	-	-	-	-
N.H.	1	-	4	3	-	-	-	-
Vt.	-	-	1	3	1	2	6	-
Mass.	22	17	6	7	-	-	-	-
R.I.	-	-	-	-	-	-	-	-
Conn.	3	2	-	-	-	-	-	-
MID. ATLANTIC	49	224	61	111	10	18	2	8
Upstate N.Y.	6	66	26	27	10	17	2	8
N.Y. City	27	60	22	45	-	-	-	-
N.J.	-	59	6	36	-	-	-	-
Pa.	16	39	7	3	-	1	-	-
E.N. CENTRAL	202	252	76	139	13	22	2	4
Ohio	133	60	30	35	-	-	2	-
Ind.	7	32	1	-	13	22	-	4
Ill.	37	90	1	47	-	-	-	-
Mich.	20	51	44	50	-	-	-	-
Wis.	5	19	-	7	-	-	-	-
W.N. CENTRAL	150	205	17	36	22	4	-	-
Minn.	20	97	-	-	-	-	-	-
Iowa	7	19	-	-	-	-	-	-
Mo.	17	49	10	19	1	-	-	-
N. Dak.	-	8	-	2	-	1	-	-
S. Dak.	91	2	-	2	1	-	-	-
Nebr.	-	10	-	2	-	1	-	-
Kans.	15	20	7	11	20	2	-	-
S. ATLANTIC	629	200	96	66	134	245	2	-
Del.	2	2	-	-	3	-	-	-
Md.	52	15	15	8	-	-	-	-
D.C.	3	8	2	-	2	1	2	-
Va.	154	11	5	21	-	-	-	-
W. Va.	1	1	-	-	3	6	-	-
N.C.	37	45	23	13	-	-	-	-
S.C.	7	12	2	1	21	40	-	-
Ga.	313	45	37	12	45	90	-	-
Fla.	60	61	12	11	60	108	-	-
E.S. CENTRAL	96	112	13	11	23	45	-	-
Ky.	18	41	1	4	1	5	-	-
Tenn.	9	12	12	7	22	39	-	-
Ala.	36	23	-	-	-	1	-	-
Miss.	33	36	-	-	-	-	-	-
W.S. CENTRAL	45	295	7	73	2	22	-	-
Ark.	16	29	-	-	2	6	-	-
La.	-	30	-	-	-	16	-	-
Okla.	28	1	6	6	-	-	-	-
Tex.	1	235	1	67	-	-	-	-
MOUNTAIN	45	82	61	57	8	10	-	-
Mont.	-	-	-	-	-	-	-	-
Idaho	2	4	1	1	-	-	-	-
Wyo.	-	-	1	-	5	-	-	-
Colo.	15	16	41	35	-	-	-	-
N. Mex.	3	19	18	15	3	10	-	-
Ariz.	13	36	-	5	-	-	-	-
Utah	5	2	-	1	-	-	-	-
Nev.	7	5	-	-	-	-	-	-
PACIFIC	209	270	64	17	-	-	-	-
Wash.	2	24	16	-	-	-	-	-
Oreg.	20	-	-	-	-	-	-	-
Calif.	179	243	39	10	-	-	-	-
Alaska	1	-	-	-	-	-	-	-
Hawaii	7	3	9	7	-	-	-	-
Guam	-	-	-	-	-	-	-	-
P.R.	-	2	-	-	-	-	-	-
V.I.	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	-	-	U	U
C.N.M.I.	-	U	-	U	-	-	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

\*Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).



TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending February 16, 2002, and February 17, 2001 (7th Week)\*

Reporting Area	Syphilis				Tuberculosis		Typhoid Fever	
	Primary & Secondary		Congenital†		Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001
	Cum. 2002	Cum. 2001	Cum. 2002	Cum. 2001				
UNITED STATES	600	630	-	62	511	990	19	30
NEW ENGLAND	7	2	-	-	17	32	3	4
Maine	-	-	-	-	-	-	-	-
N.H.	-	-	-	-	-	-	-	-
Vt.	-	-	-	-	1	1	-	-
Mass.	6	-	-	-	-	1	-	-
R.I.	-	-	-	-	5	21	2	4
Conn.	1	2	-	-	5	-	-	-
MID. ATLANTIC	51	57	-	11	6	9	1	-
Upstate N.Y.	4	1	-	-	114	152	2	13
N.Y. City	34	34	-	6	2	20	-	3
N.J.	11	7	-	-	77	67	2	1
Pa.	2	15	-	5	-	45	-	9
E.N. CENTRAL	123	88	-	-	35	20	-	-
Ohio	19	6	-	10	94	101	4	3
Ind.	7	14	-	-	21	17	2	1
Ill.	29	40	-	-	12	11	-	-
Mich.	65	25	-	9	44	57	-	1
Wis.	3	3	-	1	11	9	1	1
W.N. CENTRAL	1	14	-	-	6	7	1	-
Minn.	-	11	-	1	43	24	-	1
Iowa	-	-	-	-	22	16	-	-
Mo.	1	3	-	-	-	-	-	-
N. Dak.	-	-	-	-	21	5	-	1
S. Dak.	-	-	-	-	-	-	-	-
Nebr.	-	-	-	-	-	1	-	-
Kans.	-	-	-	-	-	2	-	-
S. ATLANTIC	144	220	-	1	-	-	-	-
Del.	1	1	-	16	36	175	5	4
Md.	11	37	-	-	-	-	-	-
D.C.	7	3	-	1	10	8	-	2
Va.	5	15	-	-	-	16	-	-
W. Va.	-	-	-	-	7	21	-	-
N.C.	48	55	-	-	5	6	-	-
S.C.	17	34	-	2	10	10	-	-
Ga.	17	28	-	5	2	16	-	-
Fla.	38	47	-	4	2	37	4	2
E.S. CENTRAL	87	74	-	4	-	61	1	-
Ky.	2	7	-	2	33	55	-	-
Tenn.	30	37	-	-	13	7	-	-
Ala.	48	16	-	1	-	8	-	-
Miss.	7	14	-	1	16	29	-	-
W.S. CENTRAL	88	93	-	-	4	11	-	-
Ark.	-	9	-	12	6	189	-	2
La.	19	18	-	2	3	13	-	-
Okla.	8	13	-	-	-	-	-	-
Tex.	61	53	-	1	3	2	-	-
MOUNTAIN	41	24	-	9	-	174	-	2
Mont.	-	-	-	2	22	37	1	1
Idaho	1	-	-	-	-	-	-	-
Wyo.	-	-	-	-	-	-	-	-
Colo.	-	2	-	-	1	-	-	-
N. Mex.	6	2	-	-	2	12	1	-
Ariz.	32	14	-	-	4	3	-	-
Utah	2	4	-	2	11	12	-	-
Nev.	-	2	-	-	2	-	-	-
PACIFIC	58	58	-	-	2	10	-	1
Wash.	6	13	-	8	146	225	4	2
Oreg.	-	2	-	-	16	23	-	-
Calif.	51	41	-	-	6	10	1	-
Alaska	-	-	-	8	96	162	3	2
Hawaii	1	2	-	-	12	8	-	-
Guam	-	-	-	-	16	22	-	-
P.R.	-	41	-	-	-	-	-	-
V.I.	-	-	-	1	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U
C.N.M.I.	1	U	-	U	8	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

\* Incidence data for reporting year 2001 and 2002 are provisional and cumulative (year-to-date).

† Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE III. Deaths in 122 U.S. cities,\* week ending February 16, 2002 (7th Week)

All Causes, By Age (Years)								All Causes, By Age (Years)								P&I <sup>†</sup> Total	
Reporting Area	All Ages	>65	45-64	25-44	1-24	<1	P&I <sup>†</sup> Total	Reporting Area	All Ages	>65	45-64	25-44	1-24	<1	P&I <sup>†</sup> Total		
NEW ENGLAND	369	285	57	19	6	2	44	S. ATLANTIC	1,394	895	314	115	40	29	104		
Boston, Mass.	U	U	U	U	U	U	U	Atlanta, Ga.	169	103	43	18	1	4	7		
Bridgeport, Conn.	43	31	7	5	-	-	5	Baltimore, Md.	157	93	43	14	5	2	20		
Cambridge, Mass.	24	22	1	1	-	-	6	Charlotte, N.C.	114	78	20	11	1	4	16		
Fall River, Mass.	U	U	U	U	U	U	U	Jacksonville, Fla.	132	90	27	8	3	4	11		
Hartford, Conn.	36	25	9	-	-	2	2	Miami, Fla.	93	56	16	13	5	3	4		
Lowell, Mass.	35	28	4	3	-	-	7	Norfolk, Va.	62	46	15	1	-	-	-		
Lynn, Mass.	9	7	1	1	-	-	2	Richmond, Va.	49	25	17	4	1	2	2		
New Bedford, Mass.	27	26	-	1	-	-	4	Savannah, Ga.	51	31	15	3	1	1	4		
New Haven, Conn.	54	38	11	2	3	-	4	St. Petersburg, Fla.	62	48	6	6	2	-	8		
Providence, R.I.	U	U	U	U	U	U	U	Tampa, Fla.	202	147	38	8	5	4	26		
Somerville, Mass.	5	4	1	-	-	-	1	Washington, D.C.	303	178	74	29	16	5	6		
Springfield, Mass.	42	32	5	3	2	-	3	Wilmington, Del.	U	U	U	U	U	U	U		
Waterbury, Conn.	25	20	4	-	1	-	6	E.S. CENTRAL	930	622	198	59	22	27	89		
Worcester, Mass.	69	52	14	3	-	-	4	Birmingham, Ala.	221	137	57	12	6	7	21		
MID. ATLANTIC	2,321	1,677	435	153	21	34	161	Chattanooga, Tenn.	97	75	15	5	1	1	8		
Albany, N.Y.	51	36	10	3	1	1	8	Knoxville, Tenn.	83	56	20	5	1	1	5		
Allentown, Pa.	28	27	1	-	-	-	4	Lexington, Ky.	58	40	12	1	2	3	9		
Buffalo, N.Y.	98	77	15	4	1	1	6	Memphis, Tenn.	195	128	45	9	6	7	17		
Camden, N.J.	29	17	6	4	1	1	2	Mobile, Ala.	68	54	6	7	1	-	7		
Elizabeth, N.J.	14	12	2	-	-	-	-	Montgomery, Ala.	42	24	12	5	1	-	6		
Erie, Pa.	42	30	7	3	1	1	1	Nashville, Tenn.	166	108	31	15	4	8	16		
Jersey City, N.J.	30	18	10	2	-	-	-	W.S. CENTRAL	990	693	207	51	18	21	95		
New York City, N.Y.	1,330	949	252	97	11	21	78	Austin, Tex.	107	72	21	10	1	3	13		
Newark, N.J.	U	U	U	U	U	U	U	Baton Rouge, La.	47	38	6	1	-	2	3		
Paterson, N.J.	21	12	6	2	-	1	1	Corpus Christi, Tex.	67	46	17	2	2	-	11		
Philadelphia, Pa.	270	174	66	21	3	5	14	Dallas, Tex.	U	U	U	U	U	U	U		
Pittsburgh, Pa. <sup>‡</sup>	26	19	2	3	1	1	4	El Paso, Tex.	60	40	9	4	3	4	5		
Reading, Pa.	29	24	4	1	-	-	5	Ft. Worth, Tex.	166	114	31	13	3	5	19		
Rochester, N.Y.	140	114	23	3	-	-	16	Houston, Tex.	U	U	U	U	U	U	U		
Schenectady, N.Y.	29	19	6	2	1	1	4	Little Rock, Ark.	75	53	15	4	-	3	3		
Scranton, Pa.	29	23	3	3	-	-	1	New Orleans, La.	U	U	U	U	U	U	U		
Syracuse, N.Y.	101	81	15	5	-	-	12	San Antonio, Tex.	314	218	73	13	7	3	21		
Trenton, N.J.	20	17	2	-	-	1	2	Shreveport, La.	20	15	4	-	1	-	5		
Utica, N.Y.	34	28	5	-	1	-	3	Tulsa, Okla.	134	97	31	4	1	1	15		
Yonkers, N.Y.	U	U	U	U	U	U	U	MOUNTAIN	1,058	750	182	84	20	17	91		
E.N. CENTRAL	1,791	1,274	348	95	36	38	134	Albuquerque, N.M.	112	72	24	10	4	1	13		
Akron, Ohio	65	53	10	1	-	1	10	Boise, Idaho	62	51	5	4	-	2	5		
Canton, Ohio	42	37	3	1	-	1	7	Colo. Springs, Colo.	80	60	11	7	-	2	5		
Chicago, Ill.	U	U	U	U	U	U	U	Denver, Colo.	U	U	U	U	U	U	U		
Cincinnati, Ohio	76	49	18	3	3	3	14	Las Vegas, Nev.	248	178	47	16	4	3	16		
Cleveland, Ohio	142	90	35	7	6	4	10	Ogden, Utah	31	28	1	2	-	-	3		
Columbus, Ohio	227	172	44	6	1	4	10	Phoenix, Ariz.	201	131	32	25	5	4	11		
Dayton, Ohio	152	111	29	9	1	2	9	Pueblo, Colo.	36	29	5	1	1	-	6		
Detroit, Mich.	158	83	48	18	3	6	9	Salt Lake City, Utah	105	70	21	6	5	3	18		
Evansville, Ind.	62	57	5	-	-	-	5	Tucson, Ariz.	183	131	36	13	1	2	14		
Fort Wayne, Ind.	71	50	13	4	3	1	4	PACIFIC	2,180	1,581	395	119	49	36	182		
Gary, Ind.	18	11	5	-	2	-	1	Berkeley, Calif.	12	9	2	-	-	1	3		
Grand Rapids, Mich.	45	36	7	1	-	1	3	Fresno, Calif.	187	144	29	9	2	3	15		
Indianapolis, Ind.	214	146	43	11	7	7	19	Glendale, Calif.	32	28	3	1	-	-	1		
Lansing, Mich.	39	29	5	4	1	-	2	Honolulu, Hawaii	103	80	17	4	-	2	7		
Milwaukee, Wis.	126	85	24	13	2	2	13	Long Beach, Calif.	77	55	13	3	4	2	14		
Peoria, Ill.	55	41	7	1	4	2	1	Los Angeles, Calif.	737	530	123	56	22	6	45		
Rockford, Ill.	66	43	17	5	-	1	7	Pasadena, Calif.	28	18	4	3	2	1	4		
South Bend, Ind.	49	40	7	1	1	-	1	Portland, Oreg.	88	58	14	11	3	2	6		
Toledo, Ohio	114	87	18	4	2	3	9	Sacramento, Calif.	162	118	32	6	4	2	16		
Youngstown, Ohio	70	54	10	6	-	-	-	San Diego, Calif.	193	132	46	7	5	3	21		
W.N. CENTRAL	745	523	148	39	16	19	63	San Francisco, Calif.	U	U	U	U	U	U	U		
Des Moines, Iowa	98	74	16	4	-	4	13	San Jose, Calif.	199	143	42	8	1	5	18		
Duluth, Minn.	U	U	U	U	U	U	U	Santa Cruz, Calif.	36	30	5	-	1	-	3		
Kansas City, Kans.	14	6	3	2	1	2	1	Seattle, Wash.	143	102	27	7	3	4	9		
Kansas City, Mo.	98	65	20	6	4	3	8	Spokane, Wash.	74	55	14	2	1	2	12		
Lincoln, Nebr.	54	39	10	2	1	2	2	Tacoma, Wash.	109	79	24	2	1	3	8		
Minneapolis, Minn.	5	3	2	-	-	-	-	TOTAL	11,778 <sup>§</sup>	8,300	2,284	734	228	223	963		
Omaha, Nebr.	126	91	22	9	1	3	16										
St. Louis, Mo.	86	52	25	5	2	2	5										
St. Paul, Minn.	111	87	19	2	3	-	10										
Wichita, Kans.	153	106	31	9	4	3	8										

U: Unavailable. - : No reported cases.

\* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of  $\geq 100,000$ . A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.<sup>†</sup> Pneumonia and influenza.<sup>‡</sup> Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.<sup>§</sup> Total includes unknown ages.

(Continued from page 148)

state their income; these nonrespondents were more likely to be elderly, Hispanic, widowed, retired, or not to have completed high school (i.e., to belong to groups that are frequently low income).

CDC has initiated activities that focus on the needs of women with diabetes. CDC's "*Diabetes and Women's Health Across the Life Stages: A Public Health Perspective*" analyzes the epidemiologic, social, and environmental dimensions of women and diabetes and discusses public health implications (8). CDC, the American Diabetes Association, the American Public Health Association, and the Association of State and Territorial Health Officials are developing a National Public Health Action Plan for Diabetes and Women. CDC is sponsoring Translating Research into Action for Diabetes (TRIAD), a 5-year prospective study of the quality of diabetes care, costs, and outcomes in managed-care settings that will examine the effects of socioeconomic status on health and quality of care. Finally, CDC is encouraging increased focus on women with diabetes through the National Diabetes Education Program, a collaborative effort with the National Institutes of Health to promote early diagnosis and improvement of the treatment and outcomes for persons with diabetes (available at <http://www.cdc.gov/diabetes/projects/ndeps.htm>); Racial and Ethnic Approaches to Community Health (REACH) 2010, a program aimed at eliminating disparities in the health status of ethnic minorities (available at <http://www.cdc.gov/reach2010>), and state-based diabetes control programs.

The low socioeconomic status of many women with diabetes poses challenges to public health practitioners. As the prevalence of diabetes continues to increase, continued and creative efforts will be needed to gain greater understanding of how socioeconomic status affects the health of women with diabetes.

#### Acknowledgement

*This report is based on data contributed by state BRFSS coordinators.*

#### References

1. Adler NE, Ostrove JM. Socioeconomic status and health: what we know and what we don't. *Ann NY Acad Sci* 1999;896:3-15.
2. Krieger N, Williams DR, Moss NE. Measuring social class in US public health research: concepts, methodologies, and guidelines. *Ann Rev Public Health* 1997;18:341-78.
3. Fiscella K, Franks P, Gold MR, Clancy CM. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. *JAMA* 2000;283:2579-84.
4. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. *Diabetes Care* 2001;24:1936-40.
5. Cowie CC, Eberhardt MS. Sociodemographic characteristics of persons with diabetes. In: National Diabetes Data Group, eds. *Diabetes in America*, 2nd ed. Bethesda, Maryland: National Institutes of Health, 1985 (NIH publication no. 85-1468).
6. Beckles GLA, Engelgau MM, Narayan KM, Herman WH, Aubert RE, Williamson DF. Population-based assessment of the level of care among adults with diabetes in the U.S. *Diabetes Care* 1998;21:1432-8.
7. Klein R, Klein BE, Jensen SC, Moss SE. The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision. *Ophthalmology* 1994;101:68-76.
8. Beckles GLA, Thompson-Reid PE, eds. *Diabetes and women's health across the life stages: a public health perspective*. Available at <http://www.cdc.gov/diabetes/pubs/english.htm>. Accessed February 2002.

All MMWR references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to [listserv@listserv.cdc.gov](mailto:listserv@listserv.cdc.gov). The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/mmwr> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/Publications/mmwr>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

☆U.S. Government Printing Office: 2002-733-100/69009 Region IV



DEPARTMENT OF HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)  
ATLANTA, GA 30333

OFFICIAL BUSINESS  
PENALTY FOR PRIVATE USE \$300  
RETURN SERVICE REQUESTED

9907 93036 N1673DS 0001  
UNIVERSITY MICROFILMS  
SERIALS ACQUISITION DEPT  
300 NORTH ZEEB ROAD  
ANN ARBOR MI 48103-1553

FIRST-CLASS MAIL  
POSTAGE & FEES PAID  
PHS/CDC  
Permit No. G-284



